Cantor Fitzgerald analyst Elemer Piros reiterated a Buy rating on Spark Therapeutics (NASDAQ: ONCE) today and set a price target of $103. The company’s shares opened today at $84.97.
Piros observed:
“We rate Spark Therapeutics Overweight. ONCE focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. With lead candidate LUXTURNA, Spark has become the first company in the U.S. with an approval for an in-vivo gene therapy product. 12-month price target is determined by the sum of the risk-adjusted NPV for the after-tax and discounted value of the programs analyzed, the value of the hemophilia A program, a platform value for the remaining pipeline and YE18 cash.”
According to TipRanks.com, Piros ‘ ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -2.9% and a 49.2% success rate. Piros covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, Strongbridge Biopharma Plc, and Global Blood Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Spark Therapeutics with a $84.67 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $96.59 and a one-year low of $41.06. Currently, Spark Therapeutics has an average volume of 552.9K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Spark Therapeutics, Inc. engages in the research, development, and commercialization of gene therapies. Its product portfolio intends to treat inherited retinal sickness, liver-mediated, and neurodegenerative diseases.
